cloudyn.png
Sunday October 2nd, 2022 9:19PM

Change at the top for Biogen after Alzheimer's drug flops

By The Associated Press
Related Articles
  Contact Editor

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.

CEO Michel Vounatsos will continue to lead the Biogen until a successor is found, the company announced Tuesday. Vounatsos joined the company in 2016 and was the chief architect of Biogen's strategy built around Aduhelm.

For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company's flagging biotech business.

The announcement represents a stark acknowledgement that the Cambridge, Massachusetts-based company has failed to find a market for a drug that was expected to drive its business for years to come.

Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster drug that would generate billions for Biogen.

But doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage over the drug’s high price tag and uncertain benefit. Even the company's decision to slash the drug's price in half— to $28,000 a year — did little to improve uptake.

The biggest setback came last month when the federal government's Medicare health plan imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. The vast majority of U.S. Alzheimer’s patients are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older.

The infused drug brought in just $2.8 million in sales in the first quarter, which ended March 31.

Biogen said Tuesday that it booked about $275 million in charges from Aduhelm inventory write-offs in the quarter, and it would essentially shutdown its sales and marketing infrastructure supporting the drug.

Aduhelm expenses dragged down the company's quarterly results and Biogen fell short of Wall Street projections, reporting adjusted net income of $535 million, or $3.62 per share. Analysts forecast earnings of $4.34 per share, according to FactSet.

Biogen executives said the restrictive Medicare decision essentially denied Aduhelm to most eligible U.S. patients. Last month the company announced it was pulling its marketing application for the drug in Europe.

Biogen will continue running a federally-mandated confirmatory trial designed to establish if the drug truly slows Alzheimer's.

The drugmaker's quarterly revenue fell 6% to $2.5 billion, pressured by lower sales of multiple sclerosis drugs in the U.S. due to cheaper, generic competition. The company also reported lower sales of its specialty drug Spinraza, which is used to treat a rare spinal disorder in children.

For the year, Biogen reaffirmed earnings guidance of between $14.25 and $16.00 per share.

Biogen executives said they will continue pursuing new Alzheimer’s treatments including a drug similar to Aduhelm. Researchers are awaiting last-stage testing results for the drug in the fall. But the company also highlighted other drugs in its pipeline, including potential treatments for depression and schizophrenia.

Vounatsos departure was expected “given the many setbacks the company has faced,” RBC Capital Markets analyst Brian Abrahams wrote Tuesday. The move and reorganization “will be well received over the long term, and give the company a fresh start in refocusing R&D priorities.”

Shares of Biogen Inc. rose less than 1%.

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2022 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Employers post record 11.5 million job openings in March
Employers posted a record 11.5 million job openings in March, more evidence of a tight labor market that has embloldened millions of American workers to leave their jobs and contributed to the biggest surge in inflation in four decades
10:51AM ( 11 minutes ago )
Live updates | EU on cusp of proposing new Russia sanctions
The European Union’s top diplomat says the bloc’s executive branch is on the cusp of proposing a new raft of sanctions against Russia
10:41AM ( 20 minutes ago )
Live updates | Ohio secretary race: Trump pick, 2020 denier
The Republican primary for Ohio secretary of state features a matchup between an incumbent endorsed by former President Donald Trump and a conservative challenger who denies that Trump lost the 2020 presidential election
10:40AM ( 22 minutes ago )
Associated Press (AP)
Change at the top for Biogen after Alzheimer's drug flops
Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled
10:21AM ( 40 minutes ago )
Ukrainian fighters: Russian forces storming Mariupol plant
Ukrainian fighters say Russian forces began storming a sprawling steel plant in the besieged port city of Mariupol on Tuesday
10:17AM ( 44 minutes ago )
US officials: Griner now considered wrongfully detained
The Biden administration has determined WNBA star Brittney Griner is being wrongfully detained in Russia, meaning the U.S. will more aggressively work to secure her release while the legal case against her plays out
10:16AM ( 46 minutes ago )
AP Business
Aid workers prep stretchers, toys for Mariupol evacuees
Aid workers prepared hot food, wheelchairs and toys for civilians slowly making their way to relative safety from the pulverized remnants of a steel plant in the city of Mariupol
8:28AM ( 2 hours ago )
Strong BP profit renews call for energy sector windfall tax
BP posted its highest quarterly profit in more than a decade thanks to surging oil and gas prices
7:56AM ( 3 hours ago )
Pfizer tops Q1 expectations, revises 2022 forecast
Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%
7:07AM ( 3 hours ago )
AP Business - Corporate News
Live updates | Russia resumes strikes on Azovstal steelworks
The Russian military says they have resumed strikes on the Azovstal steel plant in the port city of Mariupol
8:26AM ( 2 hours ago )
Wall Street points lower ahead of Fed meeting
U.S. markets pointed toward losses before markets opened on Tuesday as investors awaited a decision by the Federal Reserve on interest rates
8:19AM ( 2 hours ago )
Live updates | Finland, Sweden not decided on joining NATO
The leaders of Finland and Sweden have indicated that their governments haven’t yet decided whether to join NATO
7:35AM ( 3 hours ago )
AP Business - Industries
Mower, co-inventor of implantable defibrillator, dies at 89
A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died
6:25PM ( 1 day ago )
Q&A: Direct Relief CEO Thomas Tighe on how to help Ukraine
Helping Ukrainians can generally be done by using existing aid strategies
9:00AM ( 4 days ago )
Court says UK's nursing home COVID-19 policy was illegal
A British court has ruled that the Conservative government acted illegally when it discharged hospital patients into nursing homes without testing them for COVID-19 or isolating them
10:42AM ( 6 days ago )
AP Business - Health Care
Live updates | EU on cusp of proposing new Russia sanctions
The European Union’s top diplomat says the bloc’s executive branch is on the cusp of proposing a new raft of sanctions against Russia
10:41AM ( 20 minutes ago )
Live updates | Ohio secretary race: Trump pick, 2020 denier
The Republican primary for Ohio secretary of state features a matchup between an incumbent endorsed by former President Donald Trump and a conservative challenger who denies that Trump lost the 2020 presidential election
10:40AM ( 22 minutes ago )
Stocks drift in early going on Wall Street ahead of the Fed
Stocks drifted between small gains and losses in morning trading on Wall Street Tuesday as investors await Wednesday’s decision by the Federal Reserve on interest rates
10:33AM ( 29 minutes ago )
In Ohio, US House rematch again tests progressive clout
A rematch pitting one of the left’s rising stars against a new U.S. House incumbent backed by the more moderate Democratic establishment will provide another key litmus test of the progressive movement’s Rust Belt clout during congressional primaries in Ohio and Indiana
10:33AM ( 29 minutes ago )
DC reaches $750K settlement in Trump inaugural lawsuit
The District of Columbia attorney general says his office has reached a $750,000 settlement to resolve a lawsuit that alleged former President Donald Trump’s inaugural committee overpaid for events at the Trump International Hotel to enrich his family
10:32AM ( 29 minutes ago )